Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine (Advances in Therapy, (2019), 36, 12, (3321-3339), 10.1007/s12325-019-01126-x)

Yehuda Handelsman, Marcel H. A. Muskiet, Graydon S. Meneilly

Research output: Contribution to journalErratumAcademicpeer-review

Abstract

On page 3331 of the original article, the word, ‘‘/LYXUMIA’’ has been removed from the section RATIONALE FOR COMBINATION THERAPY COMPRISING GLP-1 RAs AND BASAL INSULIN and the associated reference, numbered 100, has been corrected to: Xultophy® (insulin degludec/liraglutide) [summary of product characteristics]. Bagsvaerd, Denmark: Novo Nordisk A/S https://www.ema.europa.eu/ en/documents/product-information/xultophyepar- product-information_en.pdf. Accessed November 2019.
Original languageEnglish
JournalAdvances in therapy
DOIs
Publication statusPublished - 2019

Cite this

@article{d79d103c76c74e83a8b3bb6ceca2fa02,
title = "Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine (Advances in Therapy, (2019), 36, 12, (3321-3339), 10.1007/s12325-019-01126-x)",
abstract = "On page 3331 of the original article, the word, ‘‘/LYXUMIA’’ has been removed from the section RATIONALE FOR COMBINATION THERAPY COMPRISING GLP-1 RAs AND BASAL INSULIN and the associated reference, numbered 100, has been corrected to: Xultophy{\circledR} (insulin degludec/liraglutide) [summary of product characteristics]. Bagsvaerd, Denmark: Novo Nordisk A/S https://www.ema.europa.eu/ en/documents/product-information/xultophyepar- product-information_en.pdf. Accessed November 2019.",
author = "Yehuda Handelsman and Muskiet, {Marcel H. A.} and Meneilly, {Graydon S.}",
year = "2019",
doi = "10.1007/s12325-019-01185-0",
language = "English",
journal = "Advances in therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",

}

TY - JOUR

T1 - Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine (Advances in Therapy, (2019), 36, 12, (3321-3339), 10.1007/s12325-019-01126-x)

AU - Handelsman, Yehuda

AU - Muskiet, Marcel H. A.

AU - Meneilly, Graydon S.

PY - 2019

Y1 - 2019

N2 - On page 3331 of the original article, the word, ‘‘/LYXUMIA’’ has been removed from the section RATIONALE FOR COMBINATION THERAPY COMPRISING GLP-1 RAs AND BASAL INSULIN and the associated reference, numbered 100, has been corrected to: Xultophy® (insulin degludec/liraglutide) [summary of product characteristics]. Bagsvaerd, Denmark: Novo Nordisk A/S https://www.ema.europa.eu/ en/documents/product-information/xultophyepar- product-information_en.pdf. Accessed November 2019.

AB - On page 3331 of the original article, the word, ‘‘/LYXUMIA’’ has been removed from the section RATIONALE FOR COMBINATION THERAPY COMPRISING GLP-1 RAs AND BASAL INSULIN and the associated reference, numbered 100, has been corrected to: Xultophy® (insulin degludec/liraglutide) [summary of product characteristics]. Bagsvaerd, Denmark: Novo Nordisk A/S https://www.ema.europa.eu/ en/documents/product-information/xultophyepar- product-information_en.pdf. Accessed November 2019.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85076924683&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31873867

U2 - 10.1007/s12325-019-01185-0

DO - 10.1007/s12325-019-01185-0

M3 - Erratum

JO - Advances in therapy

JF - Advances in therapy

SN - 0741-238X

ER -